Immunophenotypes of glycogen rich clear cell carcinoma

Yonsei Medical Journal

Volumn 53, Issue 6, 2012, Pages 1142-1146

  Kim, Sung Eun ^a   Koo, Ja Seung ^a   Jung, Woo Hee ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Breast; Carcinoma; Clear cell; Glycogen; Immunohistochemistry

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GLYCOGEN; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CLEAR CELL CARCINOMA; FEMALE; FLOW CYTOMETRY; GLYCOGEN RICH CLEAR CELL CARCINOMA; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; PARTIAL MASTECTOMY; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY;

ADENOCARCINOMA, CLEAR CELL; BREAST NEOPLASMS; FEMALE; GLYCOGEN; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; KI-67 ANTIGEN; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84868150272     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2012.53.6.1142     Document Type: Article

References (14)

1. Hull MT, Priest JB, Broadie TA, Ransburg RC, McCarthy LJ. Glycogen-rich clear cell carcinoma of the breast: a light and electron microscopic study. Cancer 1981;48:2003-9.
2. Hull MT, Warfel KA. Glycogen-rich clear cell carcinomas of the breast. A clinicopathologic and ultrastructural study. Am J Surg Pathol 1986;10:553-9.
3. Toikkanen S, Joensuu H. Glycogen-rich clear-cell carcinoma of the breast: a clinicopathologic and flow cytometric study. Hum Pathol 1991;22:81-3.
4. Fisher ER, Tavares J, Bulatao IS, Sass R, Fisher B. Glycogen-rich, clear cell breast cancer: with comments concerning other clear cell variants. Hum Pathol 1985;16:1085-90.
5. Hayes MM, Seidman JD, Ashton MA. Glycogen-rich clear cell carcinoma of the breast. A clinicopathologic study of 21 cases. Am J Surg Pathol 1995;19:904-11.
6. Kuroda H, Sakamoto G, Ohnisi K, Itoyama S. Clinical and pathological features of glycogen-rich clear cell carcinoma of the breast. Breast Cancer 2005;12:189-95.
7. Varga Z, Zhao J, Ohlschlegel C, Odermatt B, Heitz PU. Preferential HER-2/neu overexpression and/or amplification in aggressive histological subtypes of invasive breast cancer. Histopathology 2004;44:332-8.
8. Akbulut M, Zekioglu O, Kapkac M, Erhan Y, Ozdemir N. Fine needle aspiration cytology of glycogen-rich clear cell carcinoma of the breast: review of 37 cases with histologic correlation. Acta Cytol 2008;52:65-71.
9. Sutton LM, Han JS, Molberg KH, Sarode VR, Cao D, Rakheja D, et al. Intratumoral expression level of epidermal growth factor receptor and cytokeratin 5/6 is significantly associated with nodal and distant metastases in patients with basal-like triple-negative breast carcinoma. Am J Clin Pathol 2010;134:782-7.
10. De Miguel MP, Cheng L, Holland EC, Federspiel MJ, Donovan PJ. Dissection of the c-kit signaling pathway in mouse primordial germ cells by retroviral-mediated gene transfer. Proc Natl Acad Sci U S A 2002;99:10458-63.
11. Nalwoga H, Arnes JB, Wabinga H, Akslen LA. Expression of EGFR and c-kit is associated with the basal-like phenotype in breast carcinomas of African women. APMIS 2008;116:515-25.
12. Koo JS, Jung W. Clinicopathlogic and immunohistochemical characteristics of triple negative invasive lobular carcinoma. Yonsei Med J 2011;52:89-97.
13. Mahler-Araujo B, Savage K, Parry S, Reis-Filho JS. Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype. J Clin Pathol 2008;61:615-20.
14. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007;26:2157-65.